

Joint Transnational Call 2022 – JTC2022

“Prevention in Personalised Medicine”

Dr Monika Frenzel

Joint Call Secretariat 2022, The French National Research Agency, France

Infoday Presentation ERA PerMed Joint Transnational Call 2022, virtual, 09/12/2021



JTC2022 - “Prevention in Personalised Medicine”



33 funding organisations

https://erapermed.iscii.es/wp-content/uploads/2021/11/ERA-PERMED-JTC2022-%E2%80%93-REGIONAL_NATIONAL-CONTACT-DETAILS.pdf

26 countries



18 EU countries: AT, BE, DE, DK, EE, ES, FR, HR, HU, IE, IT, LT, LU, LV, PL, RO, SE, SI

3 Associated countries (H2020): IL, NO, TR

5 Third countries: BR, CA, CL, TW, ZA

1 Charity (ES)

6 EU regions: BE (Wallonia-Brussels Federation); DE (Saxony)

ES (Navarre, Catalonia); IT (Lombardy, Tuscany);



Joint Call Secretariat (JCS): Central Contact Point

The French National Research Agency

Dr Monika Frenzel / Dr Michael Joulie

+33 1 73 54 83 32 / +33 1 80 48 83 57

ERAPerMed@agencerecherche.fr



**Initial budget
29 M€ (approx.).**



Call calendar: A two-stage process

✓	01 December, 2021	Publication of the call
✓	01 December, 2021	Opening of the pre-proposals submission system
!	17 February, 2022 (17:00, CET)	Deadline for pre-proposal submission
	Expected around 11 May, 2022	Communication of the results of the pre-proposal assessment and invitation to the full-proposal stage
!	14 June, 2022 (17:00, CEST)	Deadline for full-proposal submission
!	Mid/end of August 2022	Rebuttal stage
	September 2022	Peer Review Panel (PRP) meeting and Call Steering Committee (CSC) meeting for funding recommendation to national funding agencies
	Expected for October 2022	Communication of the funding decision to the applicants
	End of 2022, beginning of 2023	Expected project start (according to regional/national funding regulations)

Information about the JTC2022

ERA PerMed website:

<https://erapermed.isciii.es/joint-calls/joint-transnational-call-2022/>

JOINT TRANSNATIONAL CALL 2022

“PREVENTION IN PERSONALISED MEDICINE”

CALL IS OPEN FOR APPLICATIONS.

Deadline for pre-proposal submission is: 17 February 2022 (17:00 CET)



➤ **Electronic submission tool:** <https://ptoutline.eu/app/erapermed2022>



➤ **Information about the JCS2022 and the involved funders**



➤ **Call documents**



➤ **Short summary of the JTC2022**

➤ **General (eligibility) conditions for application**



➤ **Partnering tool**

Call documents



Please read carefully the call text and the relevant central and regional/national eligibility and budgetary criteria before starting your proposal in order to check if you will fulfil the call's formal requirements.

- Call Text
- Guidelines for Applicants
- Pre-Proposal application form
- Full-Proposal application form (available in the full-proposal stage)

*Both, pre- and full-proposal application forms, to be uploaded on the electronic submission tool – **verify coherence of information***

Additional call documents:

- Annex: template for exploratory clinical studies (available in the full-proposal stage)
- Data Management Plan (DMP) (ONLY requested from funded proposals, available in the full-proposal stage)

Specific funders requirements

Although proposals will be submitted jointly by research groups from several regions/countries, research groups will be funded by the respective funding organisation of the region/country from which they have applied. Applicants are therefore subject to the eligibility criteria of the respective funding organisations.

- **ITALY (IT-MoH):** Pre-eligibility check form for IT-MoH proposals (to be sent to IT-MoH at least 10 working days before the JTC submission deadline).
- **ITALY (FRRB):** Pre-eligibility check form for FRRB proposals (to be sent to FRRB at least 10 working days before the JTC submission deadline) and budget tool as support for FRRB applicants.
- **ITALY (TuscReg):** Pre-eligibility check form for TuscReg proposals and budget compilation form for TuscReg proposals (both to be sent to TuscReg at least 10 working days before the JTC submission deadline).
- **SPAIN (ISCIII and FCAECC):** Additional application form for partners requesting funds from ISCIII and FCAECC (to be sent as annex of BOTH pre-proposal and full proposal submission form via the online submission tool).
- **ISRAEL (CSO-MOH):** National additional document (to be sent to CSO-MOH before the JTC submission deadline).

Aim of the 2022 call

- foster research on prevention in personalised medicine.
- development of tailor-made strategies for the prevention of disease and disease progression, at three different levels:
 - i. preventive measures to decrease the rate of incidence (**primary prevention**),
 - ii. early detection to increase the efficacy of a preventive therapy, even before symptoms develop (**secondary prevention**),
 - iii. interventions to prevent disease recurrence or to improve patient care and quality of life (**tertiary prevention**).

Research on prevention from over-treatment or overmedicalisation is optional and could be part of research proposals, if applicable.

Overall objectives of the ERA PerMed call are


- (i) to **support translational research projects in the field of Personalised Medicine;**
- (ii) to encourage and enable **interdisciplinary collaborations towards implementation of PM**, combining pre-clinical or clinical research with bio-informatics components as well as ELSA research or implementation research, including health economics;
- (iii) to **encourage collaboration** between academia, clinical/public health research and private partners.

Proposals submitted under this call are expected to demonstrate the applicability of project outcomes into clinical practice as well as to describe the impact on the healthcare systems.

Research projects in every disease entity are encouraged.

General call rules

Each proposal **MUST** address at least one module out of each research area:



Name of participating organisation	Country / Region	Funding academic or clinical/ academic partner*	Funding private partners*	Funding of Early Career Researchers (ECR)	Funding of call topic research area						Tentative initial funding commitment (M€ for 3 years)	Envisaged number of teams potentially funded with the tentative initial funding commitment
					area 1		area 2		area 3			
					1A	1B	2A	2B	3A	3B		
Austrian Science Fund, (FWF)	AUSTRIA	✓	✓	✓	✓	✓	✓	✓	✓	✓	1.5	5
Fund for Scientific Research – FNRS, (F.R.S.-FNRS)	BELGIUM/ WALLONIA-BRUSSELS FEDERATION	✓	✗	✓ (if eligible to F.R.S.-FNRS funding regulations)	✓	✗	✓	✗	✓	✓	0.2	1

Truly multidisciplinary collaborations

- **Work plan: Develop dedicated work packages with topics fitting to the modules.**
- **The partner responsible for the respective work package needs to have the appropriate expertise.**

Please consider that some regional/national funding organisations can fund only a subset of modules.

Module	1A	1B	2A	2B	3A	3B
Coordinator						
Partner 1						
Partner 2						
Partner 3						
Partner 4						
Partner 5						
WP number						

Project partner categories

- **Academia;**
 - **Clinical/public health sector;**
 - **Private for-profit (industry) partners**, e.g. SME (small and medium-sized enterprises) **and private non-profit partners**, e.g. foundations, associations or non-governmental organisations.
-
- strongly encouraged **to include partners coming from different categories – crosscutting/multidisciplinary character of the call,**
 - appropriate for the aims of the transnational research project,
 - reasonably balanced, representing the critical mass to achieve the ambitious scientific goals.

Eligibility criteria - 1

- Only transnational projects will be funded.
- **At least three partners eligible for funding from three different countries whose funders participate in the call.** All three legal entities must be independent of each other.
- At least **two partners** must be **from two different EU Member States or Associated Countries.**
- Max. 6 partners at the pre-proposal stage. Max. 7 partners at the full-proposal.

Number of partners in the proposal*	Pre-proposal				Full-proposal (only by inclusion of one underrepresented country)
		3	4	5	6

- The **project coordinator must be eligible to be funded.** No co-coordination.
- Mandatory: **at least one early-career researcher (ECR)** as principal investigator in a consortium.

Eligibility criteria - 2

Number of partners in the proposal*	Pre-proposal				Full-proposal (only by inclusion of one underrepresented country)
	3	4	5	6	7
Maximum number of partners with own funding**	0	1	1	1	1
Maximum number of partners per country***	1	2	2	2	2

- **Max. 1 partner on own funding**, e.g. from a non-funding country or not fundable according to the regional/national regulations of the participating funding organisations, in consortia with at least three partners eligible for funding.
- **Max. 2 partners from the same country including partners with their own funding.** For some funding agencies, the maximum number of eligible partners who can be funded in one project is limited to one.

EXCEPTIONS – Patient Organisations (PO)

Number of partners in the proposal*	Pre-proposal				Full-proposal (only by inclusion of one underrepresented country)
	3	4	5	6	7
Maximum number of partners with own funding**	0	1	1	1	1
Maximum number of partners per country***	1	2	2	2	2

- */** PO's are not included in this calculation → can be added as additional partners in the pre- or full-proposal stage.
- Participation of PO's either on own funds or apply for funding, if eligible for funding agency.
- Please note: **Not more than two consortium partners per country can request funding, including patient organisations.**
 - EXCEPTION: In countries with more than one funding organisation, 3 partners from the same country may apply for funding, if one of them is a PO and at least one of them is requesting funding to a regional funding organisation.

Recommendations – strongly encouraged

- Active involvement of members of the public in the proposed research projects:
 - including patients, citizens/potential patients, healthcare providers, health and social care service users as well as patient organisations
- Integrate sex and gender considerations as well as underrepresented populations (e.g. ethnic minorities), or underrepresented patient sub-groups (e.g. children or elderly):
 - including **sex distribution of research teams** AND the **inclusion of sex or gender analysis in the research *per-se***.



Both aspects are part of the evaluation criteria.


Types of studies expected to be submitted

- Inclusion of individual measurements, individual risk assessment and strategies to design tailored, preventive interventions for healthy individuals, individuals at-risk, individual patient groups or sub/populations.
- Studies have to go beyond generic health promotion research and the improvement of public health practices applicable for society as a whole.
- Small-scale exploratory clinical studies are within the scope of the call.
- **The following types of studies are outside the scope of the JTC2022:**
 - ✗ Studies on cohorts of citizens/patients exclusively based on health behaviour data.
 - ✗ Long-term behavioural studies (extending beyond 3 years).
 - ✗ Studies aiming to improve public health practices and contributing to generalisable knowledge, including studies on maintaining/enhancing health in healthy groups based solely on lifestyle information.
 - ✗ Studies that are not performed by a truly multidisciplinary consortium with expertise in all three research areas and the respective modules chosen.

Pre- and full-proposal submission forms



- **One joint proposal (in English)**, submitted only by the coordinator by uploading on the electronic submission system: <https://ptoutline.eu/app/erapermed2022>.
- **Attention:** same indications in PT-Outline and proposal templates
- **Only proposals using the official templates will be accepted**
 - Complete all fields, and respect the format of each section.
 - DIN-A4, Calibri 11, single-spaced
- **Signatures requested:**
 - Pre-proposal: only coordinator signature required
 - Full-proposal: all principle investigators have to sign
- **Respect the submission deadlines** (avoid submissions on the last moment):
 - **Deadline to submit pre-proposals: 17 February 2022 (17:00, CET)**
 - **Deadline to submit full-proposals: 14 June 2022 (17:00, CEST)**

Coordinator	Stamp and Signature
Last Name:	
First Name:	
Institution:	Date:

Eligible Annexes

- ✓ **Additional application form for partners requesting funds from ISCIII and FCAECC (BOTH pre- and full-proposal stage);**
- ✓ **Letter of commitment for a project partner participating on own funds** (free format, at every stage; mandatory in the full-proposal stage);
- ✓ **Supporting letters** (at every stage) or **endorsement letters** (at every stage) in free format.
- ✓ **Exploratory clinical studies** (at full-proposal stage) – template will be available on the ERA PerMed website;

Evaluation criteria (call text, pages 24-25)

- 1) Excellence
- 2) Impact
- 3) Quality and efficiency of the implementation

Scoring system:

0: Failure. The proposal fails to address the criterion in question, or cannot be judged because of missing or incomplete information.

1: Poor. The proposal shows serious weaknesses in relation to the criterion in question.

2: Fair. The proposal generally addresses the criterion, but there are significant weaknesses that need corrections.

3: Good. The proposal addresses the criterion in question well, but certain improvements are necessary.

4: Very good. The proposal addresses the criterion very well, but small improvements are possible.


5: Excellent. The proposal successfully addresses all aspects of the criterion in question.

Communication of the evaluation outcome

- ✓ Communication of evaluation outcomes through the JCS2022
 - First stage and second stage
Written evaluations provided to the project coordinators.
The scores will NOT be communicated.
 - Funding decision
The **consensus reports** as outcome of the Peer Review Panel will be provided to the project coordinators.



Summary




Forming consortia – ICPeMed Partnering tool



Consortia are expected to be



- Multinational
- Interdisciplinary
- Intersectoral



Forming consortia – ICPeMed Partnering tool

<https://partnering.pt-dlr.de/ICPerMed>

Describe you as potential partner

PROFILE DETAILS

EMAIL *

FIRST NAME *

LAST NAME *

AFFILIATION / INSTITUTION *

WEBSITE

TYPE OF ORGANISATION * Academia

- Clinical health
- Public health
- SME
- Industry
- Patient organisation
- Other

RESEARCH AREA *

- Basic biomedical
- genomic
- ICT
- data safety
- data management
- data use
- ELSI
- pre-clinical
- clinical
- education
- regulation
- health care
- social
- Other

COUNTRY *

REGION

DESCRIPTION OF OWN WORK

KEYWORDS (Expertise)

PUBMED

COMPETENCES OFFERED *

COMPETENCES LOOKED FOR *

PARTNERS SOUGHT FROM THESE COUNTRIES *

EXPERIENCE IN INTERNATIONAL COLLABORATIVE RESEARCH PROJECTS Yes

CONSORTIUM PARTNERS SOUGHT FOR

- ERA-PerMed
- Flagship Canada/EU
- EC Calls
- Other/specify



Forming consortia – ICPeMed Partnering tool

<https://partnering.pt-dlr.de/ICPerMed> - Search for partners

Filtertype

- show all Profiles
- regard filtersettings

Full-Text search

Profile-ID

RESEARCH AREA

- Basic biomedical
- genomic
- ICT
- data safety
- data management

TYPE OF ORGANISATION

- Academia
- Clinical health
- Public health
- SME
- Industry

CONSORTIUM PARTNERS SOUGHT FOR

- ERA-PerMed
- Flagship Canada/EU
- EC Calls
- Other/specify



Profile-ID	AFFILIATION / INSTITUTION	COUNTRY	complete profile

Forming consortia – ICPeMed Partnering tool

Of help for:

- ✓ all consortia searching for partners
- ✓ an applicant (organisation) searching for collaborations

New countries that joined the JTC2022:

- Brazil (2021), Chile (2021), Lithuania (2022), South Africa (2022), Taiwan (2022)

Underrepresented regions/countries:

- Example 2021: ANID (Chile), MSR (Croatia), ASRT (Egypt) SMWK (Saxony), VIAA (Latvia) and TUBITAK (Turkey)
- List of underrepresented countries for the JTC2022 will be available at the full-proposal stage

DO NOT FORGET



- Read carefully the call text and the relevant central and regional/national eligibility and budgetary criteria before starting your proposal in order to check if **you as partner and the consortium as a whole** fulfil the call's formal requirements.



- Contact your respective funding agency prior to submitting the application.

- anr** • Contact the Joint Call Secretariat for general questions.



- Clearly outline the **PERSONALISED MEDICINE** perspective in your research proposals.

**We are looking forward to receiving
your applications**

Questions?

<https://erapermed.isciii.es/joint-calls/joint-transnational-call-2022/>

Dr Monika Frenzel / Dr Michael Joulie

ERAPERMED@agencerecherche.fr



"This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 779282".